- Statement of Changes in Beneficial Ownership (4)

FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES	OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response... 0.5
	Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(f) of the Investment Company Act of 1940

1. Name and Address of Reporting Person * ERBA Diagnostics Mannheim GmbH	2. Issuer Name and Ticker or Trading Symbol IVAX DIAGNOSTICS INC [ IVD ]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) __ X __ Director                      __ X __ 10% Owner _____ Officer (give title below)      _____ Other (specify below)
(Last)          (First)          (Middle) MALLAUSTR 69-73,	3. Date of Earliest Transaction (MM/DD/YYYY) 4/16/2012
(Street) MANNHEIM, 2M 68219 (City)        (State)        (Zip)	4. If Amendment, Date Original Filed (MM/DD/YYYY)	6. Individual or Joint/Group Filing (Check Applicable Line) ___ Form filed by One Reporting Person _ X _ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security (Instr. 3)	2. Trans. Date	2A. Deemed Execution Date, if any	3. Trans. Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock, $0.01 par value	4/16/2012		O		600000	A	$0.75	40626313	D   (1) (4)
Common Stock, $0.01 par value								8400	I	By subsidiary   (2) (4)

Table II - Derivative Securities Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Trans. Date	3A. Deemed Execution Date, if any	4. Trans. Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Common Stock Warrants (right to buy)	$0.75	4/16/2012		O			600000	7/1/2011	7/1/2016	Common Stock, $0.01 par value	600000	$0	19400000	D   (3) (4)

Explanation of Responses:
( 1)	These shares are held directly by ERBA and indirectly by Transasia Bio-Medicals Ltd., its corporate parent, and Suresh H. Vazirani, its controlling shareholder.
( 2)	These shares are held by Erba Lachema s.r.o., a direct wholly-owned subsidiary of ERBA.
( 3)	These warrants are held directly by ERBA and indirectly by Transasia Bio-Medicals Ltd., its corporate parent, and Suresh H. Vazirani, its controlling shareholder.
( 4)	All of the reporting persons may be deemed to have beneficial ownership with respect to these securities, however, each reporting person disclaims such beneficial ownership except to the extent of his or its pecuniary interest therein.

Reporting Owners
Reporting Owner Name / Address	Relationships
	Director	10% Owner	Officer	Other
ERBA Diagnostics Mannheim GmbH MALLAUSTR 69-73 MANNHEIM, 2M 68219	X	X
Transasia Bio-Medicals Ltd. TRANSASIA HOUSE 8 CHANDIVALI STUDIO ROAD MUMBAI, IN 400072		X
Erba Lachema s.r.o. KARASEK 1D BRNO, 2N 62133		X
Vazirani Suresh H. TRANSASIA HOUSE 8 CHANDIVALI STUDIO ROAD MUMBAI, IN 400072	X	X	Executive Chairman of Board
DUDANI KISHORE TRANSASIA HOUSE 8 CHANDIVALI STUDIO ROAD MUMBAI, IN 400072	X	X

Signatures
ERBA Diagnostic Mannheim GmbH, By: /s/ Suresh Vazirani, Chief Executive Officer and Managing Director		4/16/2012
** Signature of Reporting Person		Date
Transasia Bio-Medicals Ltd., By: /s/ Suresh Vazirani, Chairman and Managing Director		4/16/2012
** Signature of Reporting Person		Date
Erba Lachema s.r.o, By: /s/ Suresh Vazirani, Statutory Body		4/16/2012
** Signature of Reporting Person		Date
/s/ Suresh Vazirani		4/16/2012
** Signature of Reporting Person		Date
/s/ Kishore Dudani		4/16/2012
** Signature of Reporting Person		Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
*	If the form is filed by more than one reporting person, see Instruction 4(b)(v).
**	Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note:	File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.